Synthesis of 1,2,3-triazole-piperazin-benzo[][1,4]thiazine 1,1-dioxides: antibacterial, hemolytic and TLR4 protein inhibitory activities.

In this study, we designed and synthesized a number of novel 1,2,3-triazole-piperazin-benzo[][1,4]thiazine 1,1-dioxide derivatives and investigated their antibacterial and hemolytic activity. When compared to the lead chemical, dicloxacillin, the majority of the compounds demonstrated acceptable activity. Among them, the most promising compounds 6e, 6g, 6i, 8d, and 8e exhibited excellent antibacterial activity against the methicillin-susceptible (MSSA), methicillin-resistant (MRSA), and vancomycin-resistant (VRSA) with MIC values of 1.56 ± 0.22 to 12.5 ± 1.75 μg mL, respectively, The percentage of hemolysis ranged from 21.3 μg mL to 33.8 μg mL. Out of the six compounds (6i, 6e, 6f, 6g, 8e, 8d) tested compound 8e and 8d displayed minimal or negligible hemolytic activity across all the tested concentrations 29.6% and 30.2% recorded at 100 μg mL concentration respectively. docking studies were performed to evaluate the molecular interactions of 6e, 6f, 6g, 6i, 8d, and 8e compounds with Human, Mouse and Bovine TLR4 proteins (PDB: 3FXI, 3VQ1, 3RG1) and observed that three of the compounds (6i, 8d, and 8i) had appreciable binding energies ranging from -8.5 to -9.0 Kcal mol. Finally, the pharmacokinetic profile was predicted for potent compounds 8d, 8e and 6i using SWISS/ADME, All compounds investigated in this study adhered to Lipinski's rule of five with slight deviation in molecular weight (8d and 8e).